MSaarinen
TL3 Regular · Santander, ES
Journal club attendee. Interested in trial design more than in trial conclusions.
Joined 31 January 2025 · last posted 4d · groups: journal-club
143Posts here
1Topics
0Solutions
3.2kLikes received
3.5kLikes given
30Badges
374Days visited
9kPosts read
Stated areas
Recent activity
Full stream-
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #50 · Compounds › Repair & healing peptides · 24 Jul 2026 · 30 likes Post #48 answers the question as asked. The question underneath it is different. Nothing in this subcategory is medical advice and several members here are describing…
-
Revisiting: Protein density versus volume when you cannot eat much Replied, post #88 · Nutrition & Training › Protein & intake · 21 Jul 2026 · 4 likes Adding the boring version of Protein density versus volume, because the interesting version keeps getting posted and the boring one is usually right. Check the ordinary…
-
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #60 · Practice › Interactions · 18 Jul 2026 · 0 likes Food interactions: most interactions are absorption interactions. Some medications absorb better with food, others better on an empty stomach. With an incretin agonist…
-
Seven-day rolling means and why weekly readings mislead Replied, post #50 · Outcomes › Progress reports · 17 Jul 2026 · 0 likes That is clearer than the version I had in my head. Thank you.
-
Revisiting: What pooling buys you and what it destroys Replied, post #92 · Evidence › Meta-analyses · 15 Jul 2026 · 15 likes Worth separating pooling buys as a question about the compound from pooling buys as a question about the documentation. They get answered by different people and only…
-
Documenting a supplier's response to a discrepancy Replied, post #33 · Sourcing › Vendor reports · 8 Jul 2026 · 17 likes Post #29 describes the usual case. This is about the unusual one. The cost of a submission is worth stating. It is the main reason people do not do this and knowing the…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #83 · Evidence › Journal club · 5 Jul 2026 · 0 likes Post #81 describes the usual case. This is about the unusual one. SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective…
-
About the Adverse events category Replied, post #5 · Safety › Adverse events · 3 Jul 2026 · 2 likes Interactions with other medicines are a common contributor to events reported here, which is why the full list matters in any report. The step people skip is the one I…
-
Pooling trials with different estimands Replied, post #65 · Evidence › Meta-analyses · 2 Jul 2026 · 10 likes Double extraction with disagreement resolution is standard and is worth checking for, because single extraction errors are common and non-random.
-
Second pass at: Programming during a large energy deficit Replied, post #47 · Nutrition & Training › Resistance training · 26 Jun 2026 · 5 likes Strength and hypertrophy respond to different things, and preserving one during a deficit is a different objective from building the other. That is my reading. Someone…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #20 · Analytics › Impurities & related substances · 24 Jun 2026 · 28 likes Worth separating two things that post #18 runs together. The honest reading of a purity figure: it is an upper bound on how much of what the method could see was the…
-
Why fasting instructions for oral semaglutide are not optional advice Replied, post #47 · Compounds › Oral incretins · 18 Jun 2026 · 0 likes I read post #43 twice before replying, because I had assumed the opposite. The gastrointestinal tolerability profile of the oral formulation is broadly similar in…
Maintains 2 documents
- SURMOUNT-4 — trial digestReview due 19 Aug 2026
- Orforglipron phase 2 (obesity) — trial digestReview due 4 Apr 2027